Investigational Drug Information for Darusentan
✉ Email this page to a colleague
What is the drug development status for Darusentan?
Darusentan is an investigational drug.
There have been 6 clinical trials for Darusentan.
The most recent clinical trial was a Phase 3 trial, which was initiated on June 1st 2006.
The most common disease conditions in clinical trials are Hypertension, Myocardial Ischemia, and Coronary Disease. The leading clinical trial sponsors are Gilead Sciences, K.Lance Gould, and [disabled in preview].
Summary for Darusentan
| US Patents | 0 |
| International Patents | 0 |
| US Patent Applications | 975 |
| WIPO Patent Applications | 503 |
| Japanese Patent Applications | 102 |
| Clinical Trial Progress | Phase 3 (2006-06-01) |
| Vendors | 35 |
Recent Clinical Trials for Darusentan
| Title | Sponsor | Phase |
|---|---|---|
| Darusentan Effect on PET Uptake Heterogeneity | Gilead Sciences | Phase 2 |
| Darusentan Effect on PET Uptake Heterogeneity | K.Lance Gould | Phase 2 |
| DORADO-AC-EX - A Long-Term Safety Extension Study to the Phase 3 DORADOC-AC Study (Protocol DAR-312) of Darusentan in Resistant Hypertension | Gilead Sciences | Phase 3 |
Clinical Trial Summary for Darusentan
Top disease conditions for Darusentan
Top clinical trial sponsors for Darusentan
US Patents for Darusentan
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
